• Home
  1. Home
  2. Effect of ritonavir on the pharmacokinetics of the benzimidazoles albendazole and mebendazole: an interaction study in healthy volunteers
Scientific article
English

Effect of ritonavir on the pharmacokinetics of the benzimidazoles albendazole and mebendazole: an interaction study in healthy volunteers

Contributors

Corti, Natascia; Heck, Antje; Rentsch, Katharina; Zingg, Walter; Jetter, Alexander; Stieger, Bruno; Pauli-Magnus, Christiane

Published in

European journal of clinical pharmacology, vol. 65, no. 10, p. 999-1006

Publication date

2009

Abstract

BACKGROUND: Benzimidazoles are often used concomitantly with protease inhibitors in patients with helminthic disease and HIV infection. Low bioavailability and extensive first-pass metabolism make benzimidazoles prone to pharmacokinetic drug interactions. The aim of the present study was to investigate potential drug interactions between the benzimidazoles albendazole and mebendazole and the potent CYP3A4 inhibitor ritonavir. METHODS: Sixteen healthy volunteers were administered a single oral dose of 1,000 mg mebendazole or 400 mg albendazole (2 x n = 8). AUC, C(max), and t(1/2) of mebendazole, albendazole, and albendazole sulfoxide were studied in absence and after short-term (2 doses) and long-term (8 days) treatment with ritonavir 200 mg bid. RESULTS: Pharmacokinetic parameters of albendazole and mebendazole were not changed by short-term administration of ritonavir. However, long-term administration of ritonavir resulted in significant changes in albendazole and mebendazole disposition, with a significant decrease in AUC(0-24) (27 and 43% of baseline for albendazole and mebendazole, respectively) and C(max) (26 and 41% of baseline, respectively). CONCLUSION: The AUC(0-24) of benzimidazoles decreased after long-term use of ritonavir, while no changes in pharmacokinetic profiles were observed under short-term administration. These findings might help to optimize benzimidazole efficacy when used in combination with protease inhibitors.

Keywords

  • Adult
  • Albendazole/administration & dosage/adverse effects/*pharmacokinetics
  • Anti-HIV Agents/pharmacology
  • Antiparasitic Agents/administration & dosage/adverse effects/*pharmacokinetics
  • Drug Interactions
  • HIV Protease Inhibitors/administration & dosage/*pharmacology
  • Humans
  • Male
  • Mebendazole/administration & dosage/adverse effects/*pharmacokinetics
  • Middle Aged
  • Reference Values
  • Ritonavir/administration & dosage/*pharmacology
  • Time Factors

UNIGE affiliation entities

Not a UNIGE publication

Citation (ISO format)

CORTI, Natascia et al. Effect of ritonavir on the pharmacokinetics of the benzimidazoles albendazole and mebendazole: an interaction study in healthy volunteers. In: European journal of clinical pharmacology, 2009, vol. 65, n° 10, p. 999–1006. doi: 10.1007/s00228-009-0683-y

Main files (1)

Article

Identifiers

Additional URL for this publication

http://www.springerlink.com/content/u3518212305n0m05/fulltext.pdf

Journal ISSN

0031-6970
641views
0downloads

Technical informations

Creation

23/04/2012 13:23:17

First validation

23/04/2012 13:23:17

Update

14/03/2023 17:24:33

Status update

14/03/2023 17:24:33

Last indexation

29/10/2024 19:29:40
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated